Kazia Therapeutics LTD (KZIA) — 6-K Filings

All 6-K filings from Kazia Therapeutics LTD. Browse 43 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (43)

6-K Filing — Mar 30, 2026
Kazia Therapeutics Files 6-K on Staff Determination Letter — Dec 19, 2025 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on December 19, 2025, reporting on a staff determination letter received on November 12, 2025. The filing is for the
Kazia Therapeutics Presents Paxalisib Data — Dec 10, 2025 Risk: medium
On December 10, 2025, Kazia Therapeutics Limited issued a press release highlighting new clinical and translational findings for its drug candidate, paxalisib.
6-K Filing — Dec 5, 2025
6-K Filing — Dec 2, 2025
6-K Filing — Nov 18, 2025
Kazia Therapeutics Files October 2025 6-K Report — Oct 7, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on October 7, 2025. The company, based in Sydney, NSW, Australia, is a foreign private issuer
Kazia Therapeutics Files 6-K Report — Oct 2, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on October 2, 2025. The company, based in Sydney, NSW, Australia, is a foreign private issuer
Kazia Therapeutics Files September 2025 6-K Report — Sep 11, 2025 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on September 11, 2025, reporting for the month of September 2025. The company, previously known as Novogen Ltd, is i
Kazia Therapeutics Announces Private Placement — Aug 1, 2025 Risk: medium
On July 31, 2025, Kazia Therapeutics Limited entered into a securities purchase agreement with certain institutional and accredited purchasers for a private pla
Kazia Therapeutics Files Form 6-K — Jul 25, 2025 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on July 25, 2025, reporting information for the month of July 2025. The company, previously known as Novogen Ltd, is
Kazia Therapeutics Files Form 6-K — Jul 9, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on July 9, 2025. The company, based in Sydney, NSW, is a foreign private issuer and is submit
Kazia Therapeutics Files Form 6-K — Jun 11, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 11, 2025. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations
Kazia Therapeutics Files 6-K with Financial Updates — Jun 10, 2025 Risk: low
Kazia Therapeutics Ltd. filed a 6-K report on June 10, 2025, detailing financial information for the period ending December 31, 2024. The report includes financ
Kazia Therapeutics Files Form 6-K — Jun 5, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 5, 2025. The company, headquartered in Sydney, NSW, is reporting for the month of Jun
Kazia Therapeutics Files May 2025 6-K Report — May 28, 2025 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on May 28, 2025, reporting its activities for the month of May 2025. The company, previously known as Novogen Ltd, i
Kazia Therapeutics Files 6-K, Formerly Novogen Ltd — May 15, 2025 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on May 15, 2025, reporting information as a foreign private issuer. The filing details the company's principal execu
Kazia Therapeutics to change ADS to Ordinary Share ratio — Apr 15, 2025 Risk: low
Kazia Therapeutics Limited announced on April 15, 2025, a planned change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares. The ratio wil
Kazia Therapeutics Files March 2025 6-K Report — Mar 31, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on March 31, 2025, reporting for the month of March 2025. The company, headquartered in Sydne
Kazia Therapeutics Files 2024 Annual Report — Mar 13, 2025 Risk: low
Kazia Therapeutics Limited filed its Annual Report to shareholders for the fiscal year ended June 30, 2024, on March 11, 2025. The report is attached as Exhibit
Kazia Therapeutics Files 6-K Report — Feb 20, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on February 20, 2025. The company, based in Sydney, NSW, operates in the pharmaceutical prepa
Kazia Therapeutics Files 6-K Report — Feb 3, 2025 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on February 3, 2025. The company, headquartered in Sydney, NSW, is a pharmaceutical preparati
Kazia Therapeutics Files January 2025 6-K Report — Jan 30, 2025 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on January 30, 2025, reporting for the month of January 2025. The company, previously known as Novogen Ltd, is based
Kazia Therapeutics Announces Registered Direct Offering — Jan 13, 2025 Risk: medium
On January 10, 2025, Kazia Therapeutics Limited entered into a securities purchase agreement with an institutional investor for a registered direct offering and
Kazia Therapeutics Files 6-K Report — Dec 31, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on December 31, 2024, reporting for the month of December 2024. The company, based in Sydney,
Kazia Therapeutics Files 6-K Report — Dec 11, 2024 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on December 11, 2024. The filing is a report of a foreign private issuer and indicates that Kazia Therapeutics Limit
Kazia Therapeutics Files Routine 6-K Report — Nov 12, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on November 12, 2024. The filing is a report of a foreign private issuer and does not specify
Kazia Therapeutics Files Routine 6-K — Nov 4, 2024 Risk: low
Kazia Therapeutics Limited, based in Sydney, NSW, filed a Form 6-K on November 4, 2024. This report is for the month of November 2024 and indicates the company
Kazia Therapeutics Changes ADS to Ordinary Share Ratio — Oct 15, 2024 Risk: low
Kazia Therapeutics Limited announced on October 15, 2024, a change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares. The ratio will chan
Kazia Therapeutics Files 6-K Report — Oct 2, 2024 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on October 2, 2024. The filing is a report of a foreign private issuer and indicates that the company files annual r
Kazia Therapeutics Files 6-K with SEC — Sep 23, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on September 23, 2024. The company, headquartered in Sydney, NSW, is a foreign private issuer
Kazia Therapeutics Files Form 6-K — Sep 13, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on September 13, 2024. The company, headquartered in Sydney, NSW, is a pharmaceutical prepara
Kazia Therapeutics Files Routine 6-K Report — Jul 10, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on July 10, 2024. The company, based in Sydney, NSW, Australia, is a foreign private issuer a
Kazia Therapeutics Files June 2024 6-K Report — Jun 24, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 24, 2024. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations
Kazia Therapeutics Faces Nasdaq Listing Deficiency — May 23, 2024 Risk: medium
Kazia Therapeutics Limited received a deficiency notification from Nasdaq on November 20, 2023, regarding its non-compliance with listing requirements. The comp
Kazia Therapeutics Reports on Warrant Issuance — May 17, 2024 Risk: low
On December 5, 2023, Kazia Therapeutics Limited issued an "Existing Warrant" allowing the purchase of up to 4,444,445 American Depositary Shares (ADSs). Each AD
Kazia Therapeutics Files 6-K Report — May 1, 2024 Risk: low
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on May 1, 2024. The company, based in Sydney, NSW, is a pharmaceutical preparations company a
Kazia Therapeutics Secures $10M Stock Purchase Agreement — Apr 19, 2024 Risk: medium
On April 19, 2024, Kazia Therapeutics Limited entered into a purchase agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its co
Kazia Therapeutics Files 6-K for Q2 2023 — Mar 27, 2024 Risk: medium
Kazia Therapeutics Ltd. filed a Form 6-K for the period ending December 31, 2023. The company, formerly Novogen Ltd., is based in Sydney, NSW, Australia. This f
Kazia Therapeutics Files 6-K Report — Mar 26, 2024 Risk: low
Kazia Therapeutics Limited filed a Form 6-K on March 26, 2024, reporting for the month of March 2024. The company, formerly known as Novogen Ltd, is based in Sy
Kazia Therapeutics Files 6-K, Confirms 20-F Annual Reporting — Feb 21, 2024 Risk: low
KAZIA THERAPEUTICS LTD, a foreign private issuer, filed a Form 6-K with the SEC on February 21, 2024. This report indicates that the company files annual report
Kazia Therapeutics Appoints Robert Apple to Board, Bolstering Leadership — Jan 18, 2024
Kazia Therapeutics Limited, a pharmaceutical company, announced on January 18, 2024, the appointment of Robert Apple to its Board of Directors, effective Januar
Kazia Therapeutics: CFO Resigns, New Financial Officer Appointed — Jan 12, 2024
Kazia Therapeutics Limited announced significant leadership changes, with Karen Krumeich resigning as Chief Financial Officer on January 8, 2024. The company qu

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX